Maravai Lifesciences (MRVI) announced Tuesday that it is postponing its Q4 earnings release and conference call from Feb. 25 to March 18.
The company said it will file a late-notification form with the US Securities and Exchange Commission and delay its annual report for the year ending Dec. 31, 2024.
Maravai added that it needs extra time to evaluate a potential non-cash impairment charge on goodwill from its acquisition of Alphazyme.
The company is assessing internal controls to fix a material weakness in its revenue recognition process and reviewing a revenue recognition error that recorded about $3.9 million in the wrong quarter, according to the company.
The error is not expected to influence the company's annual guidance, Maravai Lifesciences added.
Shares of the company were down nearly 13% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。